S&P 500   4,567.80
DOW   35,950.89
QQQ   388.83
The top-rated strong-buy stocks on Marketbeat’s radar
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
Marketbeat’s AI-powered tools for investors
Are blue chip stocks a good investment?
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
As Dollar Tree Goes, So Goes the Consumer?
Power Play: GE's game-changing technology for EVs and grids
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
Is Beyond an overlooked e-commerce winner?
Inflation in Europe falls to 2.4% as interest rates pack a punch. But the economy has stalled
S&P 500   4,567.80
DOW   35,950.89
QQQ   388.83
The top-rated strong-buy stocks on Marketbeat’s radar
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
Marketbeat’s AI-powered tools for investors
Are blue chip stocks a good investment?
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
As Dollar Tree Goes, So Goes the Consumer?
Power Play: GE's game-changing technology for EVs and grids
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
Is Beyond an overlooked e-commerce winner?
Inflation in Europe falls to 2.4% as interest rates pack a punch. But the economy has stalled
S&P 500   4,567.80
DOW   35,950.89
QQQ   388.83
The top-rated strong-buy stocks on Marketbeat’s radar
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
Marketbeat’s AI-powered tools for investors
Are blue chip stocks a good investment?
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
As Dollar Tree Goes, So Goes the Consumer?
Power Play: GE's game-changing technology for EVs and grids
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
Is Beyond an overlooked e-commerce winner?
Inflation in Europe falls to 2.4% as interest rates pack a punch. But the economy has stalled
S&P 500   4,567.80
DOW   35,950.89
QQQ   388.83
The top-rated strong-buy stocks on Marketbeat’s radar
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
Marketbeat’s AI-powered tools for investors
Are blue chip stocks a good investment?
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
As Dollar Tree Goes, So Goes the Consumer?
Power Play: GE's game-changing technology for EVs and grids
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
Is Beyond an overlooked e-commerce winner?
Inflation in Europe falls to 2.4% as interest rates pack a punch. But the economy has stalled

Protagonist Therapeutics Stock Price, News & Analysis (NASDAQ:PTGX)

$18.21
+0.52 (+2.94%)
(As of 11/30/2023 ET)
Compare
Today's Range
$17.91
$18.68
50-Day Range
$14.05
$18.21
52-Week Range
$7.34
$30.10
Volume
447,136 shs
Average Volume
1.10 million shs
Market Capitalization
$1.05 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$35.25

Protagonist Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
93.6% Upside
$35.25 Price Target
Short Interest
Healthy
6.33% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.93mentions of Protagonist Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.76) to ($2.46) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.99 out of 5 stars

Medical Sector

626th out of 949 stocks

Pharmaceutical Preparations Industry

296th out of 439 stocks


PTGX stock logo

About Protagonist Therapeutics Stock (NASDAQ:PTGX)

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of erythrocytosis, iron overload, and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that is in Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist, which is in Phase II clinical trials for inflammatory bowel disease. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

PTGX Stock Price History

PTGX Stock News Headlines

The Only Practical Solution to the World’s Looming Energy Crisis
There’s just one problem: There are more plans for new uses of nuclear than there is uranium to fuel the plants!
The Only Practical Solution to the World’s Looming Energy Crisis
There’s just one problem: There are more plans for new uses of nuclear than there is uranium to fuel the plants!
The Latest Analyst Ratings for Protagonist Therapeutics
See More Headlines
Receive PTGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Protagonist Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/02/2023
Today
11/30/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/20/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PTGX
Fax
N/A
Employees
111
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$35.25
High Stock Price Target
$38.00
Low Stock Price Target
$32.00
Potential Upside/Downside
+93.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-127,390,000.00
Pretax Margin
-16,319.91%

Debt

Sales & Book Value

Annual Sales
$26.58 million
Book Value
$5.24 per share

Miscellaneous

Free Float
54,794,000
Market Cap
$1.05 billion
Optionable
Not Optionable
Beta
1.85
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Dr. Dinesh V. Patel Ph.D. (Age 66)
    CEO, President, Secretary & Director
    Comp: $883.46k
  • Dr. Suneel K. Gupta Ph.D. (Age 65)
    Chief Development Officer
    Comp: $640.89k
  • Dr. Mark Smythe Ph.D. (Age 58)
    Founder & VP Technology
  • Mr. Asif Ali (Age 49)
    Executive VP & Chief Financial Officer
  • Mr. Mohammad Masjedizadeh Ph.D.
    Executive VP & Chief Technical Officer
  • Mr. Matthew M. Gosling (Age 52)
    Executive VP & General Counsel
  • Ms. Carena Spivey
    Senior Vice President of Human Resources
  • Dr. Ashok Bhandari Ph.D. (Age 59)
    Executive VP & Chief Drug Discovery and Preclinical Development Officer
  • Dr. Scott Eric Plevy M.D.
    Executive VP & Therapeutic Head of Gastroenterology
  • Mr. Carter J. King (Age 52)
    Senior Vice President of Business Development














PTGX Stock Analysis - Frequently Asked Questions

Should I buy or sell Protagonist Therapeutics stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Protagonist Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PTGX shares.
View PTGX analyst ratings
or view top-rated stocks.

What is Protagonist Therapeutics' stock price target for 2024?

4 brokerages have issued 1 year price targets for Protagonist Therapeutics' stock. Their PTGX share price targets range from $32.00 to $38.00. On average, they predict the company's share price to reach $35.25 in the next twelve months. This suggests a possible upside of 93.6% from the stock's current price.
View analysts price targets for PTGX
or view top-rated stocks among Wall Street analysts.

How have PTGX shares performed in 2023?

Protagonist Therapeutics' stock was trading at $10.91 at the beginning of the year. Since then, PTGX shares have increased by 66.9% and is now trading at $18.21.
View the best growth stocks for 2023 here
.

When is Protagonist Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 20th 2024.
View our PTGX earnings forecast
.

How were Protagonist Therapeutics' earnings last quarter?

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) issued its earnings results on Thursday, November, 2nd. The company reported ($0.58) earnings per share for the quarter, topping the consensus estimate of ($0.68) by $0.10.

What ETF holds Protagonist Therapeutics' stock ?

Invesco Dorsey Wright Healthcare Momentum ETF holds 129,690 shares of PTGX stock, representing 1.50% of its portfolio.

What other stocks do shareholders of Protagonist Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Protagonist Therapeutics investors own include VBI Vaccines (VBIV), Viking Therapeutics (VKTX), ImmunoGen (IMGN), SCYNEXIS (SCYX), Energy Transfer (ET), Strongbridge Biopharma (SBBP), Verastem (VSTM), Dynavax Technologies (DVAX), Novavax (NVAX) and Sorrento Therapeutics (SRNE).

When did Protagonist Therapeutics IPO?

(PTGX) raised $70 million in an IPO on Thursday, August 11th 2016. The company issued 5,800,000 shares at a price of $11.00-$13.00 per share. Leerink Partners, Barclays and BMO Capital Markets acted as the underwriters for the IPO.

Who are Protagonist Therapeutics' major shareholders?

Protagonist Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Kynam Capital Management LP (3.15%), Braidwell LP (1.92%), 683 Capital Management LLC (1.27%), Adage Capital Partners GP L.L.C. (1.21%), Northern Trust Corp (0.98%) and Hsbc Holdings PLC (0.96%). Insiders that own company stock include David Y Liu, Dinesh V Ph D Patel and Sarah B Noonberg.
View institutional ownership trends
.

How do I buy shares of Protagonist Therapeutics?

Shares of PTGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:PTGX) was last updated on 12/1/2023 by MarketBeat.com Staff

My Account -